FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL								
l	OMB Number:	3235-0287							
l	Estimated average burden								

0.5

hours per response:

	Check this box if no longer subject to							
)	Section 16. Form 4 or Form 5							
J	obligations may continue. See							
	Instruction 1(h)							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					01	Ocou	011 00(11) 0	71 1110	IIIVESUIIEIIL	••••	ipariy 7 tot	0. 20 .0								
1. Name ar		2. Issuer Name <b>and</b> Ticker or Trading Symbol Akero Therapeutics, Inc. [ AKRO ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)									
Young Jonathan						AKETO THETAPEUTICS, IIIC. [ AKRO ]									Directo	Director		10% Ow	ner	
(Landa (Einea) (Middle)															Officer (give title below)			Other (s below)	pecify	
(Last) (First) (Middle) C/O AKERO THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 12/13/2019									Chief Operating Officer					
170 HAF	RBOR WAY	, 3RD FLOOR																		
(Street)					4.1	f Ame	ndment, [	Date (	of Original F	iled	(Month/Da	6. Individual or Joint/Group Filing (Check Applicable Line)								
SOUTH SAN CA		A	94080											iled by One Reporting Person						
FRANCI	SCO -				,	Form filed by More than One Reporting Person									ting					
(City)	(S	tate)	(Zip)																	
		Tab	le I - Nor	ı-Deriv	ative	e Se	curities	s Ac	quired, I	Disp	oosed o	f, or Be	enefi	cially	Owned					
1. Title of Security (Instr. 3)  2. Transar Date (Month/Da						ear)   i	2A. Deemed Execution Date, if any (Month/Day/Year		, Transaction Dispo		Disposed	rities Acquired (A) ed Of (D) (Instr. 3,		4 and Securi Benefi Owned		ies For cially (D) Following (I) (		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	Amount (A) or (D)		rice	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)	
		-	Table II -						uired, Di						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, T	4. Transaction Code (Instr 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				C	Code	v	(A)	(D)	Date Exercisabl		expiration Date	Title	Amo or Nun of Sha	nber						
Stock Option (Right to Buy)	\$21.09	12/13/2019			A		85,000		(1)	1	2/12/2029	Common Stock	85,	000	\$0	85,000	)	D		

## **Explanation of Responses:**

1. This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 13, 2019.

/s/ Jonathan Young

12/13/2019

\*\* Signature of Reporting Person

Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly.$ 

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.